Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 2/2013

01-06-2013 | Original Paper

Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report

Authors: Wade Iams, Kathyrn Eby Beckermann, Anne T. Neff, Ingrid A. Mayer, Vandana Gupta Abramson

Published in: Medical Oncology | Issue 2/2013

Login to get access

Abstract

Chemotherapy-induced thrombotic microangiopathy is a severe illness that has occurred in a small number of patients treated with carboplatin and combination of docetaxel and trastuzumab chemotherapy. We describe herein the case of a patient with stage IIB breast cancer who developed thrombotic microangiopathy after five cycles of carboplatin, docetaxel, and trastuzumab.
Literature
1.
Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy; incidence, prevention, and management. Drug Saf. 2001;24(7):491–501.PubMedCrossRef
2.
Symmers W. Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br Med J. 1952;2:897–903.PubMedCrossRef
3.
Siau K, Varughese M. Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report. Med Oncol. 2010;27:1057–9.PubMedCrossRef
4.
Murgo AJ. Cancer- and chemotherapy-associated thrombotic microangiopathy. In: Kaplan BS, Trompeter RS, Moake JL, editors. Hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura, (kidney disease S v. 10), vol. 22. New York: Marcel Dekker Ltd; 1992. p. 271–95.
5.
Rahdi M, Carpenter SL. Thrombotic microangiopathies. ISRN Hematol. 2012.
6.
7.
Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia. Medicine. 2012;91:195–205.PubMedCrossRef
8.
Walker RW, Rosenblum MK, Kempin SJ, Christian MC. Carboplatin-associated thrombotic microangiopathic hemolytic anemia. Cancer. 1989;64(5):1017–20.PubMedCrossRef
9.
Fisher DC, Sherrill GB, Hussein A, Rubin P, Vredenburgh JJ, Elkordy M, Ross M, Petros W, Peters WP. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transpl. 1996;18(1):193–8.
10.
Dlott JS, Danielson CFM, Blue-Hnidy DE, McCarthy LJ. Drug induced thrombotic thrombocytopenic purpura/haemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004;8(2):102–11.PubMedCrossRef
11.
Fields SM, Lindley CM. Thrombotic microangiopathy associated with chemotherapy: case report and review of the literature. DICP. 1989;23(7-8):582–8.PubMed
12.
Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol. 1985;3(5):723–34.PubMed
13.
Snyder HW Jr, Mittelman A, Oral A, Messerschmidt GL, et al. Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma. Cancer. 1993;71(5):1882–92.PubMedCrossRef
14.
Onitilo AA, Engel JM, Clouse LH, Gerndt KM. Successful treatment of mitomycin-induced thrombotic thrombocytopenic purpura with rituximab. Vasc Interv Radiol. 2009;20(2):275–6.CrossRef
Metadata
Title
Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report
Authors
Wade Iams
Kathyrn Eby Beckermann
Anne T. Neff
Ingrid A. Mayer
Vandana Gupta Abramson
Publication date
01-06-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0568-x

Other articles of this Issue 2/2013

Medical Oncology 2/2013 Go to the issue

Short Communication

Polymorphisms in genes of APE1, PARP1, and XRCC1: risk and prognosis of colorectal cancer in a Northeast Chinese population

Original Paper

A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer

Original Paper

Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer

Original Paper

IL-32 expression is an independent prognostic marker for gastric cancer

Original Paper

Overexpression of TFIIB-related factor 2 is significantly correlated with tumor angiogenesis and poor survival in patients with esophageal squamous cell cancer

Original Paper

Association between single nucleotide polymorphisms of the transforming growth factor-beta1 gene and overall survival in unresectable locally advanced non-small-cell lung cancer patients treated with radio(chemo)therapy in a Chinese population

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits